financetom
Technology
financetom
/
Technology
/
UBS Maintains Buy Rating for Lam Research: Here's What You Need To Know
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UBS Maintains Buy Rating for Lam Research: Here's What You Need To Know
Mar 5, 2024 9:31 AM

UBS has decided to maintain its Buy rating of Lam Research ( LRCX ) and raise its price target from $885.00 to $1130.00.

Shares of Lam Research ( LRCX ) are trading down 1.16% over the last 24 hours, at $966.14 per share.

A move to $1130.00 would account for a 16.96% increase from the current share price.

About Lam Research

Lam Research ( LRCX ) is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segments of deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear cut second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Computer chip group SEMI to EU: new export controls should be 'last resort'
Computer chip group SEMI to EU: new export controls should be 'last resort'
Mar 5, 2024
AMSTERDAM, March 5 (Reuters) - The European Union should think twice before imposing additional export controls or rules on foreign investment, semiconductor industry group SEMI Europe said in a position paper published this week. The warning comes after the European Commission in January presented a package of plans aimed at improving economic security and preventing unwanted technology transfers to rivals...
UBS Maintains Buy Rating for Lam Research: Here's What You Need To Know
UBS Maintains Buy Rating for Lam Research: Here's What You Need To Know
Mar 5, 2024
UBS has decided to maintain its Buy rating of Lam Research ( LRCX ) and raise its price target from $885.00 to $1130.00. Shares of Lam Research ( LRCX ) are trading down 1.16% over the last 24 hours, at $966.14 per share. A move to $1130.00 would account for a 16.96% increase from the current share price. About Lam...
Apple's iPhone sales in China plunge 24% as Huawei's popularity surges
Apple's iPhone sales in China plunge 24% as Huawei's popularity surges
Mar 5, 2024
BEIJING (Reuters) -Apple's iPhone sales in China fell 24% year-on-year in the first six weeks of 2024, according to research firm Counterpoint, as the U.S. company faced increased competition from domestic rivals such as Huawei. The U.S. tech giant's chief competitor in China in premium smartphones, Huawei, saw unit sales rise by 64% in the period, according to the report....
CloudMD Software & Services Reports Multi-Service Contract With The Ottawa Hospital
CloudMD Software & Services Reports Multi-Service Contract With The Ottawa Hospital
Mar 5, 2024
12:40 PM EST, 03/05/2024 (MT Newswires) -- CloudMD Software & Services Inc. ( DOCRF ) said Tuesday that it has signed a multi-service contract with The Ottawa Hospital. Under the contract, the company will provide The Ottawa Hospital's more than 15,000 team members access to the full Kii, by CloudMD suite of services, including Nurse Navigation, Employee Family Assistance Plan,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved